Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

NCT04425239 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

151

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Stage IV

Interventions

DRUG: Panitumumab
DRUG: Panitumumab

Sponsor

National Cancer Institute, Naples